HOME >> BIOLOGY >> NEWS
HIV-Positive Injection Drug Users Often Don't Receive Protease Inhibitors And May Not Be Aware Of The Drug

GENEVA, Switzerland--A significant number of injection drug users in San Francisco who are HIV-positive do not receive protease inhibitors and may not even be aware of these medications--despite a commitment on the part of the city to make these drugs widely available.

"We found a lot of drug users were not taking the therapies, even though they were theoretically available to them. Many had not heard of the therapies, and some of them had heard of them but were still not taking them for whatever reasons," said Brian R. Edlin, MD, of the University of California San Francisco.

In a presentation here today (July 2) at the 12th World AIDS Conference, Edlin reported findings from a UCSF study on HIV therapy availability and adherence. Lead study investigator, he is a UCSF associate professor of health policy and community medicine and director of the UCSF Urban Health Study. Edlin noted that there is a bias against providing protease inhibitors, the powerful anti-HIV medications, to injection drug users because they are perceived as being poor adherers to treatment.

Nonetheless, the city has made it a policy to provide full access to these medications to all HIV-positive individuals. Federal guidelines also recommend that practitioners not discriminate in prescribing therapy on the basis of injection drug use, he said.

The UCSF research team set out to determine if, in fact, injection drug users were receiving the therapies.

Between October 1997 and March 1998, the research team interviewed 668 injection drug users in four San Francisco neighborhoods, testing them for HIV and questioning them about their knowledge of available HIV treatments. The researchers also conducted in-depth interviews with about a dozen individuals to help understand what factors might prevent or encourage those who were HIV-positive to adhere to combination therapy.

Sixty-three of the study participants (9.4 percent) were found to be HIV-positive.
'"/>

Contact: Corinna Kaarlela
corinna@irtsa.ucsf.edu
(415) 476-3804
University of California - San Francisco
2-Jul-1998


Page: 1 2 3

Related biology news :

1. Nationwide Study Finds HIV-Positive Women Are At High Risk For Cervical Human Papillomavirus Infection
2. Injection prevents blinding blood vessel growth in mice
3. Groundwater Injection Process Filters Out Contaminants
4. Bugscope Gives Internet Users Anywhere Chance To Study Insects
5. Hopkins Study Shows Brain Damage Evidence In "Ecstasy" Users
6. UF Researchers: Gene Therapy Replaces Critical Protein In Animal Model Of Often-Fatal Lung-Liver Disease
7. HIV Patients Often Experience Viral "Breakthrough," But May Still Remain Healthy, San Francisco Study Finds
8. Research Shows That If One Identical Twin Is Prey To Nightmares, Often The Other Is Too
9. Dont always believe what you see, suggests study on false memories
10. Dont drink the water: Texas A&M researcher conducting study of polluted Mexican lake
11. Dont ban embryo-based research says new chairman of European fertility organisation

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/8/2019)... ... May 08, 2019 , ... FISO Technologies proudly ... microns and a lead-in fiber of 100 microns. With dimensions smaller than any ... itself as the world leader in the development of fiber optic sensors & ...
(Date:5/7/2019)... ... May 07, 2019 , ... AMGtime will be ... Entertainment Center from May 15- 17. At booth #226, AMGtime will be showcasing ... software, biometric hardware, mobile apps, specialized industry solutions, advanced add-on modules, seamless integrations, ...
(Date:5/2/2019)... ... April 30, 2019 , ... Global molecular ... today that Holotype HLA and other Omixon products will be featured in 12 ... (EFI) in Lisbon, Portugal. Among the major scientific events, Omixon’s Lunch ...
Breaking Biology News(10 mins):
(Date:4/9/2019)... SANTA BARBARA, Calif. (PRWEB) , ... April 09, ... ... global professional services firm focused on increasing the capacity of life sciences organizations ... to its Cloud Assurance platform in the past 12 months. , ...
(Date:4/9/2019)... ... April 09, 2019 , ... The American Society ... of the Society's leadership team, including a new addition to the presidential line of ... their peers to join the Society's leadership team for a three-year term (2019-2021). , ...
(Date:4/8/2019)... ... , ... US Capital Global Securities , an affiliate of US Capital ... privately held pharmaceutical company, S1 Biopharma (“S1”). , S1 has a pipeline of drugs ... dysfunction disorder and is ready to begin phase 2b trials. In phase 2a trials, ...
(Date:4/4/2019)... , ... April 02, 2019 , ... ... solutions, announced it would be releasing it’s latest field-ready solution for performing PCR, ... Biomeme’s next-gen thermocycler Franklin™ pays homage to Rosland Franklin, an English chemist and ...
Breaking Biology Technology:
Cached News: